84
Participants
Start Date
January 25, 2017
Primary Completion Date
June 6, 2018
Study Completion Date
August 29, 2018
Glecaprevir/Pibrentasvir
Fixed-dose combination tablets taken orally once a day.
Auckland Clinical Studies Ltd /ID# 157033, Auckland
Wits Clinical Research Site /ID# 157038, Johannesburg
Nepean Hospital Kingswood /ID# 157027, Kingswood
UZ Leuven /ID# 157030, Leuven
Royal Melbourne Hospital /ID# 157024, Parkville
Royal Brisbane and Women's Hospital /ID# 157025, Herston
University of Cape Town /ID# 157039, Cape Town
AZ Groeninge /ID# 157029, Kortrijk
Einstein Medical Center /ID# 157436, Philadelphia
Hopital Haut-Lévêque /ID# 157035, Pessac
CHU Estaing /ID# 157034, Clermont-Ferrand
Hopital Saint Antoine /ID# 157036, Paris
Cedars-Sinai Medical Center - West Hollywood /ID# 157045, West Hollywood
Research & Education, Inc. /ID# 157042, San Diego
Hopital Beaujon /ID# 157028, Clichy
Kaiser Permanente /ID# 157044, San Diego
Zuckerberg San Francisco Gener /ID# 157040, San Francisco
University of Washington /ID# 157041, Seattle
National Hospital of Tropical Diseases /ID# 162282, Hanoi
National University Hospital /ID# 156855, Singapore
Singapore General Hospital /ID# 157037, Singapore
Hoa Hao Medic Co. Ltd. /ID# 162283, Ho Chi Minh City
University of Calgary /ID# 157031, Calgary
Toronto General Hospital /ID# 157032, Toronto
Tropical Diseases Hospital /ID# 162281, Ho Chi Minh City
Lead Sponsor
AbbVie
INDUSTRY